ERBB2 and neoplasm: Klampatsa et al. (2017) developed panErbB (EGFR (ErbB1), HER2 (ErbB2), ErbB3, and ErbB4)-directed CAR-T cells which also expressed IL-4 receptor to allow for CAR-T cell proliferation and found that intraperitoneal injection of these CAR-T cells mediated tumor regression in a mouse model of MPM [33].